Segment Information - Schedule of Segment Reporting Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Segment Reporting Information [Line Items]
Revenues	$ 22,058	$ 27,172
Cost of revenues	894	979
Gross profit	21,164	26,193
Operating expenses excluding cost of revenues:
Selling and marketing	10,841	12,542
Research and development	3,095	2,182
General and administrative	4,955	3,398
Total operating expenses excluding cost of revenues	18,891	18,122
Income (loss) from operations	2,273	8,071
Change in fair value of warrant liability	2,255	4,288
Other income, net	107	122
Income tax expense	(901)	(2,546)
Net income	3,734	9,935
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation	507	11
Total assets	129,790		$ 125,406
Purchase of property and equipment	122	231
General and administrative
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation	507	11
Gyre Pharmaceuticals
Segment Reporting Information [Line Items]
Revenues	22,058	27,172
Cost of revenues	894	979
Gross profit	21,164	26,193
Operating expenses excluding cost of revenues:
Selling and marketing	10,841	12,542
Research and development	3,029	2,009
General and administrative	3,556	2,257
Total operating expenses excluding cost of revenues	17,426	16,808
Income (loss) from operations	3,738	9,385
Other income, net	62	62
Income tax expense	(901)	(2,546)
Net income	2,899	6,901
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation	78
Total assets	122,351		114,248
Purchase of property and equipment	122	217
Gyre Pharmaceuticals | General and administrative
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation	78
Gyre
Operating expenses excluding cost of revenues:
Research and development	66	173
General and administrative	1,396	1,141
Total operating expenses excluding cost of revenues	1,462	1,314
Income (loss) from operations	(1,462)	(1,314)
Change in fair value of warrant liability	2,255	4,288
Other income, net	45	60
Net income	838	3,034
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation	429	11
Total assets	7,074		10,790
Purchase of property and equipment		14
Gyre | General and administrative
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation	429	$ 11
Other
Operating expenses excluding cost of revenues:
General and administrative	3
Total operating expenses excluding cost of revenues	3
Income (loss) from operations	(3)
Net income	(3)
Supplemental disclosure of stock-based compensation expense:
Total assets	$ 365		$ 368